湖南南新制药股份有限公司 关于以集中竞价交易方式回购公司股份的 进展公告

Group 1 - The company has approved a share repurchase plan, intending to buy back shares worth between RMB 10 million and RMB 20 million, with a maximum price of RMB 9.53 per share, within a 12-month period [2][3] - As of December 2025, the company has repurchased a total of 1,910,214 shares, representing 0.70% of the total share capital, with a total expenditure of RMB 16,138,029.08 [3] - The repurchase activities are in compliance with relevant laws and regulations [4] Group 2 - The company announced the resignation of independent director Shen Yunqiao due to personal reasons, which may affect the composition of the board and its committees [8][9] - The company will expedite the process of electing a new independent director to ensure compliance with legal and regulatory requirements [8]